Taysha Gene Therapies (TSHA) Accumulated Depreciation (2020 - 2026)

Taysha Gene Therapies has disclosed Accumulated Depreciation across 7 years of filings, most recently posting $5.0 million for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $5.0 million, up 30.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (up 30.28% YoY), and the FY2025 annual result was $4.7 million, up 30.69% from the prior year.
• Accumulated Depreciation came in at $5.0 million for Q1 2026 at Taysha Gene Therapies, up from $4.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $5.0 million in Q1 2026 to a low of $754000.0 in Q1 2022.
• The 5-year median for Accumulated Depreciation is $3.3 million (2024), against an average of $3.0 million.
• Across the five-year window, Accumulated Depreciation jumped 1739.02% in 2022 and gained 12.03% in 2025, its largest moves.
• Taysha Gene Therapies' Accumulated Depreciation stood at $1.6 million in 2022, then soared by 81.43% to $3.0 million in 2023, then advanced by 20.31% to $3.6 million in 2024, then surged by 30.69% to $4.7 million in 2025, then rose by 6.19% to $5.0 million in 2026.
• The last three Accumulated Depreciation figures came in at $5.0 million (Q1 2026), $4.7 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.